1
with a BRCA2 mutation 11-17% of women Up to References: 1 Cancer Research UK: Risk Factors for Ovarian Cancer. Available at: http://www.cancerresearchuk.org/cancer-info/cancerstats/types/ovary/riskfactors/ Last accessed: March 2017 2 SEER Cancer Factsheets: Ovary cancer. SEER 18 2003-2009. Available at: http://seer.cancer.gov/statfacts/html/ovary.html Last accessed: March 2017 3 Gadzicki D, et al. Genetic testing for familial/hereditary breast cancer—comparison of guidelines and recommendations from the UK, France, the Netherlands and Germany. J Community Genet. 2011;2:53-69. 4 National Cancer Institute. BRCA1 and BRCA2: Cancer Risk and Genetic Testing. http://www.cancer.gov/cancertopics/factsheet/Risk/BRCA Last accessed: March 2017 5 Cancer Genome Atlas Network. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474:609-15. 6 World Cancer Research Fund. Ovarian cancer statistics. Available from: http://www.wcrf.org/int/cancer-facts-figures/data-specific-cancers/ovarian-cancer-statistics Last accessed; March 2017 © 2017 AstraZeneca. All Rights Reserved Ovarian cancer is the 7 th most commonly diagnosed cancer in women worldwide 6 Several factors may influence the development and prognosis of ovarian cancer, including 1,2 : of ovarian cancers are diagnosed at the advanced stage 2 Family history 92% 73% 28% Stage I Stage II/III Stage IV 5-YEAR SURVIVAL 5-year survival decreases significantly with stage of diagnosis 2 Lifestyle factors Environmental factors Age Early diagnosis OVARIAN CANCER AND GENETIC TESTING Genetic mutations can play a role in the development and treatment of cancer Individuals at risk of carrying a genetic mutation can be referred for genetic testing 3 BRCA1 and BRCA2 belong to a type of genes known as tumour suppressors 4 The risk of developing ovarian cancer is increased in women with specific inherited genetic abnormalities. One of these risks is associated with BRCA mutations 5 will develop ovarian cancer by age 70 years 4 in the general population About 1.3% of women with a BRCA1 m ation ut Up to 39% of women 60% Up to of women who inherit a BRCA1 mutation are likely to develop ovarian cancer 4 Up to of women who inherit a BRCA2 mutation are likely to develop ovarian cancer 39% 11 - 17% Document Number: Z4-4913 Date of Prep: May 2017 Date of expiry: May 2018

Ovarian cancer 7 L A V I 60% - AstraZeneca · for ge ntic s 3 BRCA1 and BRCA2 belong to a type of genes known as tumour suppressors 4 The risk of developing ovarian cancer is increased

Embed Size (px)

Citation preview

with aBRCA2 mutation

11-17%of women

Up to

References:1 Cancer Research UK: Risk Factors for Ovarian Cancer. Available at: http://www.cancerresearchuk.org/cancer-info/cancerstats/types/ovary/riskfactors/ Last accessed: March 20172 SEER Cancer Factsheets: Ovary cancer. SEER 18 2003-2009. Available at: http://seer.cancer.gov/statfacts/html/ovary.html Last accessed: March 20173 Gadzicki D, et al. Genetic testing for familial/hereditary breast cancer—comparison of guidelines and recommendations from the UK, France, the Netherlands and Germany. J Community Genet. 2011;2:53-69.4 National Cancer Institute. BRCA1 and BRCA2: Cancer Risk and Genetic Testing. http://www.cancer.gov/cancertopics/factsheet/Risk/BRCA Last accessed: March 20175 Cancer Genome Atlas Network. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474:609-15.6 World Cancer Research Fund. Ovarian cancer statistics. Available from: http://www.wcrf.org/int/cancer-facts-figures/data-specific-cancers/ovarian-cancer-statistics Last accessed; March 2017

© 2

017

Astra

Zene

ca. A

ll Rig

hts

Rese

rved

Ovarian cancer is the 7th most commonly diagnosed cancer in women worldwide 6

Several factors may influence the development and prognosis of ovarian cancer, including 1,2:

of ovarian cancers are diagnosed at the advanced stage 2

Familyhistory

92%

73%

28%

Stage I

StageII/III

StageIV

5-YE

AR S

URV

IVAL

5-year survival

decreases significantly

with stage of diagnosis2

Lifestylefactors

Environmental factors

Age Earlydiagnosis

OVARIAN CANCER AND GENETIC TESTINGGenetic mutations can play a role in the development and treatment of cancerIndividuals at risk of carrying a genetic mutation can be referred for genetic testing3

BRCA1 and BRCA2 belong to a type of genes

known as tumour suppressors 4

The risk of developing ovarian cancer is increased in women with specific inherited genetic abnormalities. One of these risks is associated with BRCA mutations5

will develop ovarian cancer

by age 70 years

4

in the generalpopulation

About 1.3% of women

with aBRCA1 m ationut

Up to 39% of women

60% Up to

of women who inherit a BRCA1

mutation are likely to develop ovarian

cancer

4

Up to

of women who inherit a BRCA2

mutation are likely to develop ovarian

cancer

39%

11 - 17%

Docu

men

t Num

ber:

Z4-4

913

D

ate

of P

rep:

May

201

7

Dat

e of

exp

iry: M

ay 2

018